Literature DB >> 10361243

In vivo modulation of cytokine synthesis by intravenous immunoglobulin.

W A Sewell1, M E North, R Cambronero, A D Webster, J Farrant.   

Abstract

We examined the effects of intravenous immunoglobulin (IVIG) on cytokine regulation in vivo using samples taken before and after replacement-dose (200-400 mg/kg) IVIG in a group of patients with common variable immunodeficiency (CVID) and X-linked agammaglobulinaemia (XLA). The intracellular cytokine content of CD4+ and CD8+ lymphocytes, and their CD28+/- subsets, were measured following in vitro activation with phorbol myristate acetate (PMA) and ionomycin. The cytokines IL-2, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), and the early activation marker CD69, were assessed by four-colour flow cytometry of whole blood cultures taken before and after IVIG infusion. There was a significant increase in IL-2 expression in CD4+ (and CD4+28-) cells and an increase in TNF-alpha expression in CD8+28- cells following IVIG in CVID, but not in XLA patients. IFN-gamma and CD69 expression were not affected by IVIG infusion. This increase in TNF-alpha and IL-2, combined with unchanged IFN-gamma expression, is evidence against the putative 'anti-inflammatory' role of IVIG, and may explain the failure of resolution of granulomata in CVID patients treated with IVIG alone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361243      PMCID: PMC1905312          DOI: 10.1046/j.1365-2249.1999.00924.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

Authors:  I N van Schaik; I Lundkvist; M Vermeulen; A Brand
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

Review 2.  Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure.

Authors:  B Sander; J Andersson; U Andersson
Journal:  Immunol Rev       Date:  1991-02       Impact factor: 12.988

Review 3.  The use of intravenous immune globulin in immunodeficiency diseases.

Authors:  R H Buckley; R I Schiff
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

4.  Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immune globulin.

Authors:  M Ballow; W White; C Desbonnet
Journal:  J Allergy Clin Immunol       Date:  1989-10       Impact factor: 10.793

5.  Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.

Authors:  S Reitamo; A Remitz; J Varga; M Ceska; F Effenberger; S Jimenez; J Uitto
Journal:  Arch Dermatol       Date:  1993-02

6.  Evidence that defective gamma interferon production in patients with primary immunodeficiencies is due to intrinsic incompetence of lymphocytes.

Authors:  R Paganelli; M R Capobianchi; B Ensoli; G P D'Offizi; J Facchini; F Dianzani; F Aiuti
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

7.  Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG.

Authors:  U G Andersson; L Björk; U Skansén-Saphir; J P Andersson
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

8.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

9.  Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo.

Authors:  Z D Ling; E Yeoh; B T Webb; K Farrell; J Doucette; D S Matheson
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

10.  In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins.

Authors:  M Toungouz; C H Denys; D De Groote; E Dupont
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

View more
  10 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Intravenous immunoglobulin and dendritic cells.

Authors:  Namita Misra; Jagadeesh Bayry; Jagadeesh Bayary; Sooryasarathi Dasgupta; Amal Ephrem; Jean-Paul Duong Van Huyen; Sandrine Delignat; Gazzala Hassan; Giuseppina Caligiuri; Antonino Nicoletti; Sebastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 5.  Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.

Authors:  S V Kaveri; M S Maddur; P Hegde; S Lacroix-Desmazes; J Bayry
Journal:  Clin Exp Immunol       Date:  2011-06       Impact factor: 4.330

6.  Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study.

Authors:  Karolina Kasztalska; Maciej Ciebiada; Barbara Cebula-Obrzut; Paweł Górski
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

7.  In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency.

Authors:  Hasibe Artac; Reyhan Kara; Ismail Reisli
Journal:  Clin Exp Med       Date:  2010-03       Impact factor: 3.984

Review 8.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

9.  Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency.

Authors:  Tri Dinh; Jun Oh; Donald William Cameron; Seung-Hwan Lee; Juthaporn Cowan
Journal:  PLoS One       Date:  2019-10-15       Impact factor: 3.240

10.  A decreased frequency of regulatory T cells in patients with common variable immunodeficiency.

Authors:  Karina M Melo; Karina I Carvalho; Fernanda R Bruno; Lishomwa C Ndhlovu; Wassim M Ballan; Douglas F Nixon; Esper G Kallas; Beatriz T Costa-Carvalho
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.